The Effect of Gluten on Gut Microbiome and Metabolic Health.

Not Applicable

Completed

• Conditions: Metabolic Diseases; Injury of Gastrointestinal Tract
• Interventions: Other: High gluten; Other: Low gluten

• Registration Number: NCT01719913
• Lead Sponsor: University of Copenhagen

Brief Summary

Objective: To identify how specific changes of the gluten content in the diet affect the host-gut microbiome interactions with implications for metabolic health.

Design: A randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. A total number of 60 participants will be included.

Intervention: low vs high gluten intake.

Detailed Description

The study is designed as a randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. A total number of 60 participants will be included. Participants consume, in randomized order, a gluten-poor diet (\<5 g/d) in the active treatment period and a gluten-rich diet (\>25 g/d) during the control period.

Measurements: Altered quantitative metagenomics at bacterial gene- and species levels is the primary outcome of this study. Secondary outcomes include metabolic and inflammatory markers, circulating appetite hormone levels,serum metabolomics, gastrointestinal transit time and intestinal permeability. Furthermore, selected control measures are included; 4-day food records and a study intervention dietary records.

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2012-10-24
• Study First Submitted QC: 2012-10-30
• Study First Posted: 2012-11-01
• Primary Completion: 2013-11
• Study Completion: 2013-11
• Status Verified: 2013-12
• Last Update Submitted: 2013-12-04
• Last Update Posted: 2013-12-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

• Pharmacological treatment; diabetes and blood lipid regulation
• Lactating (or lactating, 6 weeks ago), pregnant (or pregnant, 3 months ago) or wish to become pregnant during the study
• Participation in another biomedical trial 1 month prior to study start
• Diagnosed with any form of diabetes, celiac disease or chronic pancreatitis
• Reported chronic gastrointestinal disorders
• Antibiotic treatment for 3 month prior to study start
• Blood hemoglobin < 7.0 mmol/l
• Blood donation within 1 month prior to study start

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
High gluten	High gluten	Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
Low gluten	Low gluten	Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)

Primary Outcome Measures

Name	Time	Method
Altered quantitative metagenomics at bacterial gene- and species levels.	Up to 3 years.	Feces samples are collected according to standard operation procedures for subsequent standardized microbial DNA extraction. Microbial DNA will be subjected to sequencing, microbial gene analyses, taxonomy analyses including enterotypes known species and unknown meta-species and functional annotation.

Secondary Outcome Measures

Name	Time	Method
C-peptide	Up to 2 years.	Fasting.
Colonic fermentation	Up to 2 years.	Breath hydrogen after intake of standardized breakfast (30,60,90,120,180 minutes)
Mean intestinal transit time	Up to 2 years.	Participants are instructed in swallowing capsules containing different small non-invasive and non-absorbable plastic pellets for 6 consecutive days. On the seventh day they are having an X-ray of the abdomen taken.
Gastrointestinal permeability.	Up to 2 years.	Lactulose/mannitol ratio in urine after four hours collection following oral intake of lactulose and mannitol.
Blood pressure and pulse.	Up to 1 year.	Systolic and diastolic blood pressure and heart beat rate are measured after 10 min of rest according to current standard operational procedure with an automatic blood pressure meter. Participants are instructed not to talk during the measurements.
Saliva microbial flora	Up to 2 years.	Saliva is collected after the participants have taken a small piece of paraffin in their mouth and have chewed until the paraffin has turned into one coherent mass (approximately one minute). Participants are swallowing the produced saliva for that minute. After this, and for the next 3 minutes, saliva is collected in a cup and handed over to the study personnel. Saliva is stored at minus 80 degrees for later studies of saliva microbial flora and saliva biochemistry.
Nasal fluid	Up to 3 years.	Nasal fluid is collected by a non-invasive methodology for in vivo measurement of an array of immunological signalling molecules in the nasal airway lining. The method is based on a standardized collection of mucosal airway fluid from both nostrils onto small sheets of filter papers with efficient absorption properties. The technique is highly reproducible, and used for measuring immunological mediators representing the immediate response ability of the mucosal immune system.
Appetite hormones	Up to 3 years.	Glucagon like peptide 1 and 2, Gastric inhibitory polypeptide, peptide YY and Ghrelin.
Celiac disease markers	Up to 1 year.	Levels of gliadin and Immunoglobulin A and G transglutaminase.
Blood lipid profile	Up to 2 years.	Low density Lipoproteins, High density lipoproteins, Total Cholesterol, Very low density lipoproteins and Free fatty acids.
Bioimpedance	Up to 1 year.	Body composition (lean body mass and fat mass) is measured by bio-electrical impedance using multi frequency Quadscan.
Breath hydrogen.	Up to 2 years.	Breath hydrogen measurements are done before the intake of the standardized breakfast (at 30, 60, 90, 120, 180 minutes), as an indicator of colonic fermentation.
Insulin	Up to 2 years.	Fasting insulin and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal.
Glucose	Up to 2 years.	Fasting glucose and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal.
Inflammatory makers	Up to 3 years.	High sensitive C-reactive protein, Interleukin 1, 6 and 10, Lipopolysaccharide- binding protein, Tumor necrosis factor - alfa.
Anthropometric characteristics.	Up to 1 year.	Weight, height, sagittal height and waist circumference.

Trial Locations

Locations (1)

The Novo Nordisk Foundation of Basic Metabolic Health, Section for Metabolic Genetics; 🇩🇰 Copenhagen, Denmark